Enter your vial size and bacteriostatic water volume to get syringe units per dose. Mechanism, trial record and the full test history sit on the Cagrilintide peptide guide.
A 10 mg vial of Cagrilintide reconstituted with 2 mL of bacteriostatic water gives a concentration of 5 mg/mL, or 50 mcg per unit on a U-100 syringe. For a 0.75 mg dose, draw the syringe to 15 units (0.15 mL). At that dose the vial provides about 13 doses.
Draw the syringe up to
That's one 250 mcg dose. Add 2 mL of water to your 10 mg vial first.
Draw the syringe up to 15 units (0.15 mL). That's one 0.75 mg dose. Add 2 mL of water to your 10 mg vial first.
Cagrilintide dose figures only mean something once you state the concentration. A 10 mg vial reconstituted with 2 mL of bacteriostatic water is 5 mg/mL, which is 50 mcg per unit on a U-100 syringe, so a 0.75 mg starting dose is 15 units (0.15 mL) and the vial holds about thirteen of them. Change the water volume and the unit count changes while the drug in the vial does not. This page gives you the arithmetic, the dose figures that have a trial behind them, reconstitution steps, third-party purity results and per-mg price.
The arithmetic is deterministic; the dose figures below are labelled by their own evidence level, because Cagrilintide is not approved for any indication and no regulator has approved a dose for it anywhere.
| Vial + water | Concentration | mcg per unit (U-100) | 0.75 mg dose | Doses per vial |
|---|---|---|---|---|
| 10 mg + 1 mL | 10 mg/mL | 100 mcg | 7.5 units (0.075 mL) | about 13 |
| 10 mg + 2 mL (default) | 5 mg/mL | 50 mcg | 15 units (0.15 mL) | about 13 |
| 10 mg + 3 mL | 3.33 mg/mL | 33.3 mcg | 22.5 units (0.225 mL) | about 13 |
| 10 mg + 4 mL | 2.5 mg/mL | 25 mcg | 30 units (0.30 mL) | about 13 |
Every figure in this table is arithmetic on the 10 mg vial: concentration = vial mg ÷ water mL; mcg per unit = concentration mg/mL × 1,000 ÷ 100; units = dose mcg ÷ mcg per unit; doses per vial = vial mg ÷ dose mg. Doses per vial is about 13 in every row because adding more water dilutes the same 10 mg — it changes how far you push the plunger, never how much drug is in the vial.
Cagrilintide at 5 mg/mL delivers 50 mcg per unit, so a 0.75 mg dose is 15 units; at 10 mg/mL the same 0.75 mg dose is 7.5 units, which is a poor reading on a U-100 barrel; at 2.5 mg/mL it is 30 units. A units figure quoted without a concentration cannot be used. That resolution point is the argument for the more dilute default: the same drug, four times the reading resolution, at the amount most people will draw first.
Cagrilintide has no approved label, so there is no authoritative dose. Every figure in circulation traces to one of three places: the Phase 2 monotherapy dose range of 0.3 mg to 4.5 mg weekly, the 0.75 mg starting dose with monthly increments to 4.5 mg described in our science article, or the 2.4 mg component amount inside the CagriSema fixed-dose combination. The intermediate steps of the escalation are not stated anywhere in this fact base, and this page does not invent them.
Cagrilintide is a long-acting analog of human amylin, activating calcitonin and amylin receptors and acting in the brainstem and hypothalamus on satiety, gastric emptying and energy balance. Its half-life is approximately 7 days, which is what makes once-weekly subcutaneous dosing possible.
| Route | Amount | Frequency | Duration | Evidence level |
|---|---|---|---|---|
| Subcutaneous | 0.3 mg to 4.5 mg | Once weekly | Phase 2 | Human trial — the stated Phase 2 dose range |
| Subcutaneous | 0.75 mg | Once weekly | Starting dose | Stated protocol, science article |
| Subcutaneous | 4.5 mg | Once weekly | 44 weeks | Human trial — the Lancet 2023 monotherapy arm |
| Subcutaneous | 2.4 mg | Once weekly | — | The cagrilintide component of CagriSema |
| Escalation | “Monthly increments” from 0.75 mg to 4.5 mg | Once weekly | To 4.5 mg/week | Protocol shape only — the size of each increment is not stated anywhere in this fact base |
| Any regulator-approved dose | None exists anywhere | |||
Cagrilintide's Phase 2 dose range was 0.3 mg to 4.5 mg once weekly; our science article describes a 0.75 mg weekly starting dose with monthly increments to 4.5 mg weekly over a 44-week treatment period; the CagriSema combination carries a 2.4 mg cagrilintide component. No regulator has approved any of them.
Two different figures are published for the same 4.5 mg weekly monotherapy dose. Our compound page records 10.8% weight loss at 4.5 mg, n=706, over 26 weeks. Our science article records −15.6% average body weight loss over 44 weeks at once-weekly 4.5 mg (The Lancet, 2023). These are different durations — 26 weeks against 44 — so they may describe two different readouts rather than contradicting each other, but neither source says so. Both are printed here with their duration; neither is presented as the Cagrilintide result, and they are not averaged.
The mechanism and the trial evidence behind these amounts are set out in the Cagrilintide science article.
Draw volumes depend entirely on the concentration you mixed. At the page default of 5 mg/mL every amount with a trial figure behind it fits inside one 1 mL U-100 barrel: 0.3 mg is 6 units, the 0.75 mg starting dose is 15 units, the 2.4 mg CagriSema component amount is 48 units and the 4.5 mg top of the Phase 2 range is 90 units. That is unusual for a weight-loss peptide, and it is the reason 2 mL is the default water volume here.
| Tier | Amount | What it is | Draw at 5 mg/mL | Volume | Fits a 1 mL U-100 barrel? |
|---|---|---|---|---|---|
| Lowest Phase 2 amount | 0.3 mg | Bottom of the stated Phase 2 range | 6 units | 0.06 mL | Yes |
| Starting dose | 0.75 mg | Stated starting dose, science article | 15 units | 0.15 mL | Yes |
| Combination component | 2.4 mg | The cagrilintide half of CagriSema | 48 units | 0.48 mL | Yes |
| Top of the Phase 2 range | 4.5 mg | Highest amount with a trial figure | 90 units | 0.90 mL | Yes |
Line by line: 0.3 mg once weekly is 6 units (0.06 mL) at 5 mg/mL; 0.75 mg is 15 units (0.15 mL); 2.4 mg is 48 units (0.48 mL); 4.5 mg is 90 units (0.90 mL). The intermediate escalation steps between 0.75 mg and 4.5 mg are not stated in this fact base, so no unit figure is printed for them.
| Amount | At 2.5 mg/mL (10 mg + 4 mL) | At 5 mg/mL (10 mg + 2 mL) | At 10 mg/mL (10 mg + 1 mL) |
|---|---|---|---|
| 0.3 mg | 12 units | 6 units | 3 units |
| 0.75 mg | 30 units | 15 units | 7.5 units |
| 2.4 mg | 96 units | 48 units | 24 units |
| 4.5 mg | 180 units — does not fit a 1 mL barrel | 90 units | 45 units |
Every cell is the same arithmetic — units = (dose mg ÷ concentration mg/mL) × 100 — applied to the amounts in the table above. At 5 mg/mL every amount with a trial figure behind it fits in a single 1 mL U-100 barrel; at 2.5 mg/mL the 4.5 mg amount needs 180 units and does not; at 10 mg/mL the 0.75 mg starting dose falls to 7.5 units, where a misread of half a unit is a 7% dosing error. The same arithmetic for other compounds: how to calculate peptide doses.
Reconstitution here is a choice, not a recipe — no label sets a diluent volume for Cagrilintide and no page in our fact base states one, so the volume you pick is the one that puts your intended dose in a readable part of the syringe. Pick the water volume first, add it slowly against the inside glass wall, then refrigerate. The one rule with real consequences is resolution.
| Step | 10 mg in 1 mL | 10 mg in 2 mL |
|---|---|---|
| Concentration | 10 mg/mL | 5 mg/mL |
| Volume for the 0.75 mg starting dose | 0.075 mL | 0.15 mL |
| U-100 units | 7.5 units — poor resolution | 15 units |
The same 0.75 mg starting dose is 7.5 units from a 10 mg vial in 1 mL and 15 units from the same vial in 2 mL — identical drug, twice the reading resolution. Diluent choice and the sterile-versus-bacteriostatic distinction are covered once, elsewhere: bacteriostatic water guide and reconstituting peptides step by step.
A vial lasts as many weeks as the label mass divided by the weekly amount — water volume changes nothing about it. Only two vial sizes are tracked, 5 mg and 10 mg, so the table covers both against the four amounts with a figure behind them.
| Vial size | At 0.3 mg/wk | At 0.75 mg/wk | At 2.4 mg/wk | At 4.5 mg/wk |
|---|---|---|---|---|
| 5 mg | about 16.7 weeks | about 6.7 weeks | about 2.1 weeks | about 1.1 weeks |
| 10 mg | about 33.3 weeks | about 13.3 weeks | about 4.2 weeks | about 2.2 weeks |
Arithmetic: weeks = vial mg ÷ weekly mg. A 10 mg vial at 0.75 mg once weekly lasts about 13 weeks; at 4.5 mg once weekly, about 2 weeks. A 5 mg vial at 0.75 mg lasts about 7 weeks; at 4.5 mg, about 1 week.
These durations are label mass divided by dose. They say nothing about whether a reconstituted vial is still good that long — see the missing in-use period above — and nothing about whether the vial contains the labelled mass. Why label mass and delivered mass diverge: why 10 mg isn't 10 mg.
Cagrilintide is one of the more heavily tested compounds on this platform. It holds a Purity Index of 99.65 across 253 recency-weighted tests from 20 labs, ranking 16th of the 64 indexed compounds as of September 2026, and its 90-day trend is improving (▲ 0.03). The compound page separately records 262 tests on file at an average HPLC purity of 99.62% across 225 shops listed. That establishes that vendors are broadly selling the correct molecule. It says nothing about efficacy, dosing or long-term safety.
253 tests in the recency-weighted Purity Index; 262 tests on file on the compound page (both as of September 2026). The two counts differ because the index counts published certificates as of 1 September 2026 and weights them by recency. Likewise 99.62% is the unweighted average HPLC purity from the compound page, while 99.65 is the recency-weighted index value — not a conflict, but two different measurements.
Index methodology, in the Purity Index's own words: “Each compound's index is the mean of its published HPLC purity results, weighted by recency: a test within 90 days counts at full weight, one within a year at 0.6, and older tests at 0.3.” Individual certificates: Cagrilintide lab test records.
Cagrilintide's median tracked price is $11.90 per mg and the lowest tracked is $3.00 per mg, on a 10 mg vial, across 47 shops in stock and 55 of 68 listings comparable per milligram — all as of 10 August 2026, the date the price layer last refreshed. At the median, the 0.75 mg starting dose is about $8.93 of compound and a 4.5 mg dose about $53.55. Vials run $30.00 to $263.99 and the per-mg spread across the whole market is $3.00 to $34.00.
| Field | Value (as of 10 August 2026) |
|---|---|
| Median | $11.90/mg |
| Lowest tracked | $3.00/mg — 10 mg vial, sold only as a multi-vial kit |
| Shops in stock | 47, all with third-party lab tests on file |
| Offers comparable per mg | 55 of 68 listings identified |
| Coverage | 126 shops known to sell Cagrilintide; 53 with a live listing; 73 evidenced by a lab test |
| Vial price range | $30.00–$263.99 |
| Per-mg range | $3.00–$34.00 |
| Vial sizes tracked | 5 mg and 10 mg |
Cost per dose is dose mg × $/mg. At the $11.90/mg median: 0.3 mg = $3.57; 0.75 mg = $8.93; 2.4 mg = $28.56; 4.5 mg = $53.55. At the $3.00/mg lowest tracked: 0.75 mg = $2.25; 4.5 mg = $13.50.
These figures exclude shipping, taxes and customs charges; coupon codes and bulk tiers; multi-vial kits; and email-only or account-required pricing. They are the lowest tracked price, not the lowest payable price. The 225 shops listed on the compound page, the 47 in stock and the 126 known to sell are three different denominators and are not the same figure. Full offers table and price history: Cagrilintide price per milligram.
Cagrilintide is an amylin receptor agonist; semaglutide is a GLP-1 agonist; CagriSema is the fixed-dose combination of the two in a single weekly injection. For this calculator the practical difference is that the amounts are similar in scale — 2.4 mg of each inside CagriSema — so a syringe reading means roughly the same amount of drug across the three. The regulatory position is the same for all three: none is approved.
| Factor | Cagrilintide | CagriSema |
|---|---|---|
| Mechanism | Amylin and calcitonin receptor agonist, acting in the brainstem and hypothalamus | Fixed-dose combination of cagrilintide + semaglutide in one weekly injection |
| Typical amount | 0.75 mg weekly starting, to 4.5 mg weekly | 2.4 mg cagrilintide + 2.4 mg semaglutide, once weekly |
| Half-life | Approximately 7 days | Not stated on the source page |
| Headline trial figure | 10.8% at 4.5 mg, n=706, 26 weeks — and −15.6% over 44 weeks at 4.5 mg; see above | REDEFINE 1: 20.4% at 68 weeks |
| Regulatory status | Not approved for any indication as of May 2026; Phase 3 REDEFINE and REIMAGINE | NDA filed with the FDA 18 December 2025; unapproved in the US and EU as of August 2026 |
These figures come from separate trials in different populations and are not head-to-head comparisons.
REDEFINE 1 has two published numbers and they are not interchangeable. 20.4% at 68 weeks is the published primary result, on the treatment-policy estimand, and is the figure this page states. A separate 22.7% figure exists on the trial-product estimand; it is a different analysis of the same trial, not a higher reading of the same one, and the two do not form a range.
A page that quotes REDEFINE 1 without REDEFINE 4 is selectively reporting, so: in REDEFINE 4, CagriSema delivered 23% weight loss but did not meet its primary endpoint of noninferiority to tirzepatide at 25.5%. The combination is covered in full on the CagriSema compound guide.
Cagrilintide is not approved for any indication as of May 2026 and is in Phase 3 for obesity (the REDEFINE programme) and Phase 3 for type 2 diabetes (REIMAGINE), with an NDA filing expected in 2026–2027 and potential FDA approval in 2027–2028. Our science article states the same position with an earlier as-of date: not yet approved by the FDA or EMA as of February 2026, under review for approval in 2026–2027. Both dates are printed because both sources carry them.
The combination product moves faster: Novo Nordisk filed an NDA for CagriSema on 18 December 2025, it remains unapproved in the US and EU as of August 2026, and an FDA decision is anticipated in Q4 2026 with no official PDUFA date announced.
Equipment, not technique: syringe and needle sizing for Cagrilintide. Category bridge: the weight-loss compound index.
It depends on the concentration. At the page default of 5 mg/mL (10 mg vial + 2 mL), 0.75 mg is 15 units on a U-100 syringe. At 10 mg/mL it is 7.5 units, and at 2.5 mg/mL it is 30 units. A units figure quoted without a concentration cannot be used.
There is no approved one. The Phase 2 range was 0.3 mg to 4.5 mg once weekly, and our science article describes a 0.75 mg weekly starting dose with monthly increments to 4.5 mg weekly across a 44-week treatment period. The size of each increment is not stated in our fact base, so this page does not print a ladder.
There is no standard volume and no label to specify one. 2 mL gives 5 mg/mL, which keeps every amount from 0.3 mg to 4.5 mg between 6 and 90 units on a 1 mL U-100 barrel. 1 mL gives 10 mg/mL and pushes the 0.75 mg starting dose down to 7.5 units.
Cagrilintide is the amylin receptor agonist on its own. CagriSema is the fixed-dose combination of cagrilintide plus semaglutide in a single weekly injection, typically 2.4 mg of each. Neither is approved: cagrilintide is in Phase 3, and CagriSema has an NDA filed with the FDA and a decision anticipated in Q4 2026.
Divide the label mass by the weekly amount. A 10 mg vial at 0.75 mg weekly is about 13 weeks; at 4.5 mg weekly it is about 2 weeks. A 5 mg vial at 0.75 mg weekly is about 7 weeks. How long the reconstituted solution stays usable is a separate question, and no in-use period for Cagrilintide appears in our fact base.
No. The 253 indexed tests establish that vendors are broadly selling the correct molecule at high purity. A certificate confirms identity and purity; it does not confirm the mass in your particular vial, and the difference between labelled and delivered mass moves every draw proportionally.